Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€217.00

€217.00

-1.450%
-3.2
-1.450%
-
 
11:02 / Tradegate WKN: 716563 / Symbol: SUVPF / Name: Sartorius / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Sartorius AG VZO Stock

We can see a decrease in the price for Sartorius AG VZO. Compared to yesterday it has lost -€3.200 (-1.450%).
For the coming years our community has positive and negative things to say abot the Sartorius AG VZO stock. Criterium "Credit Rating" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Pros and Cons of Sartorius AG VZO in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sartorius AG VZO vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sartorius AG VZO -1.450% -9.345% 0.502% -36.670% -33.635% -55.739% 13.564%
Sartorius AG ST 0.770% -4.097% 2.354% -34.079% -30.833% -61.598% 4.046%
Healthequity Inc. 5.110% -2.837% -11.613% 22.321% 15.126% 10.199% -
Integer Hldg 1.750% 0.885% 6.542% 48.052% 28.090% 50.993% 56.507%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Looking at the financial statements of Sartorius (US symbol SUVPF), a company in the Healthcare Equipment & Supplies industry, it appears that the company has been experiencing growth over the past few years. Its assets, liabilities, and equity have all increased over time. Furthermore, the company's revenue and net income have been on an upward trajectory, indicative of consistent financial progress. However, to form a more comprehensive understanding of the company's financial health, it is essential to delve deeper and examine the pros and cons of the financial statements provided.

Growing Revenue: Sartorius' total revenue has been on the rise over the years, reaching EUR 4.17 billion in 2022. The steady growth signals a strong demand for the company's products and services, which is a positive indicator for its overall business performance.

Increase in Net Income: The net income of the company has also consistently grown, culminating in EUR 678.1 million in 2022. This indicates that the company is not only generating more revenue but is also effectively managing its expenses, leading to higher profitability.

Comments

Buy Sartorius AG VZO
Show more

Buy Sartorius AG VZO
Show more

Prediction Buy
Perf. (%) 88.73%
Target price 180.000
Change
Ends at 30.04.19

(Laufzeit überschritten)
Show more

News

EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024